Imperial Chemical Industries Limited

Astrazeneca Ab

Zeneca Limited

Howard Tucker

John Oldfield

Peter Warner

David Waterson

Gloria Anne Breault

Leslie R Hughes

Nicholas John Newcombe

Bernard Christophe Barlaam

Maurice Raymond Verschoyle Finlay

Robert I Dowell

Alan Wellington Faull

Christophe B Barlaam

Maurice R V Finlay

Gloria Ann Breault

Robert Ian Dowell

Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal). 

Piperidine derivatives as modulators of chemokine receptor CCR5

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13 

Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)

Compounds of formula (I): wherein L is CH or N; M is CH or N; provided that L and M are not both CH; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal) 

Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)

Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Metalloproteinase inhibitor compounds

Arylpiperazines of Formula I useful as metalloproteinase inhibitors, especially as MMP13 inhibitors.

Inhibitors of metalloproteinases

Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists

Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Compounds

Compounds of the formula, ##STR1## and pharmaceutically-acceptable salts thereof, which are useful as antagonists of the pain-enhancing effects of E-type prostaglandins, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating pain comprising the administration of such compounds.

Substituted aryl and heteroaryl compounds as E-type prostaglandin

Ortho-substituted aromatic ether compounds and their use in

Aromatic amino ethers as pain relieving agents

This invention relates to substituted and unsubstituted ���(aryl- and heteroaryl-) alkyl-, alkyloxy-, alkylthio-, oxo-, thio-, and alkylamino!- heteroaryl and aryl!- alkylamino-, aminoalkyl-, alkyloxy-, and alkylthio!- aryl and heteroaryl compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, which are useful as antagonists of the pain enhancing effects of E-type prostaglandins, to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods for treating pain comprising the administration of such compounds.

Ortho substituted aromatic compounds useful as antagonists of the pain

The invention relates to tricyclic heterocycles of the formula I ##STR1## wherein X is oxy, thio, sulphinyl, sulphonyl, amino, (1-4C)alkylamino or methylene;

Growing community of inventors

Macclesfield, United Kingdom

Howard Tucker